ARCT Stock Analysis: Buy, Sell, or Hold?
ARCT - Arcturus Therapeutics Holdings Inc. Common Stock
$7.08
-0.15 (-2.07%)
▼
5d:
-3.41%
30d:
+0.85%
90d:
+3.06%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When ARCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ARCT shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: ARCT shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: ARCT is currently trading at $7.08, which is considered slightly low relative to its 30-day fair value range of $6.95 to $7.66.
Technical Outlook: Technically, ARCT is showing sideways momentum. Immediate support is located at $6.71, while resistance sits at $7.87.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.89 (+180.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ARCT is showing sideways momentum. Immediate support is located at $6.71, while resistance sits at $7.87.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.89 (+180.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$6.95 -
$7.66
Company Quality Score
56/100
(HOLD)
Options IV Signal
19th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 19th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 180.9% below Wall St target ($19.89)
Trading Range Analysis
30-Day Trading Range
$6.95 -
$7.66
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.55
(7.7%)
Support & Resistance Levels
Support Level
$6.71
Resistance Level
$7.87
Current Trend
Sideways
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.77
Wall Street Target
$19.89
(+180.9%)
Revenue Growth (YoY)
-93.0%
Profit Margin
-143.8%
Share & Embed Analysis
Last updated: June 23, 2026 11:39 PM ET
Data refreshes hourly during market hours. Next update: 12:39 AM
Data refreshes hourly during market hours. Next update: 12:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
